Results 61 to 70 of about 205,719 (255)

KRAS: Druggable at Last

The Oncologist, 2023
The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.
Benjamin O Herzberg, Gulam A Manji
openaire   +2 more sources

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles [PDF]

, 2019
Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy.
Bi, Ye, Brooks, Candace, DeNardo, David G, Fields, Ryan C, Fleming, Timothy, Gillanders, William E, Goedegebuure, S Peter, Hawkins, William G, Krasnick, Bradley A, Pan, Hua, Sankpal, Narendra, Strand, Matthew S, Wetzel, Christopher, Wickline, Samuel A, Zhang, Xiuli   +14 more
core   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. [PDF]

, 2019
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with no efficacious treatment options. PDAC incidence is projected to increase, which may be caused at least partially by the obesity epidemic.
Eibl, Guido, Rozengurt, Enrique
core  

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. [PDF]

, 2012
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN). Treatment with the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs with mucinous metaplasia and
Butler, Peter C, Dawson, David, Dry, Sarah M, Gier, Belinda, Kirakossian, David, Matveyenko, Aleksey V   +5 more
core   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Ewolucja pozycji Narodowego Banku Polskiego w polityce makroostrożnościowej

Seminare, 2017
Artykuł poświęcony jest pozycji Narodowego Banku Polskiego w nadzorze makroostrożnościowym. Pierwotnie za nadzór makroostrożnościowy w Polsce miała odpowiadać Rada Ryzyka Systemowego, w której próbowano zagwarantować wiodącą rolę NBP z różnym nasileniem.
Ireneusz Kraś
doaj  

KRAS-mutated non-small cell lung cancer: new therapy strategies

Сибирский онкологический журнал
Lung cancer remains one of the most dangerous and most common cancers, requiring constant improvement of diagnostic and treatment methods. The genetic heterogeneity of lung cancer forces us to search for new therapeutic targets in an attempt to achieve ...
K. K. Laktionov, K. A. Sarantseva, L. A. Nelyubina, S. V. Gamayunov, E. A. Kolesnikova, M. G. Gordiev   +5 more
doaj   +1 more source

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis

Health Technology Assessment, 2014
Background: Bowel cancer is the third most common cancer in the UK. Most bowel cancers are initially treated with surgery, but around 17% spread to the liver. When this happens, sometimes the liver tumour can be treated surgically, or chemotherapy may be
Marie Westwood, Thea van Asselt, Bram Ramaekers, Penny Whiting, Manuela Joore, Nigel Armstrong, Caro Noake, Janine Ross, Johan Severens, Jos Kleijnen   +9 more
doaj   +1 more source